null
Loading... Please wait...
FREE SHIPPING on All Unbranded Items LEARN MORE
Print This Page

Transforming Big Pharma (Assessing the Strategic Alternatives)

List Price: $55.99
SKU:
9781032837338
Quantity:
Minimum Purchase
25 unit(s)
  • Availability: Confirm prior to ordering
  • Branding: minimum 50 pieces (add’l costs below)
  • Check Freight Rates (branded products only)

Branding Options (v), Availability & Lead Times

  • 1-Color Imprint: $2.00 ea.
  • Promo-Page Insert: $2.50 ea. (full-color printed, single-sided page)
  • Belly-Band Wrap: $2.50 ea. (full-color printed)
  • Set-Up Charge: $45 per decoration
FULL DETAILS
  • Availability: Product availability changes daily, so please confirm your quantity is available prior to placing an order.
  • Branded Products: allow 10 business days from proof approval for production. Branding options may be limited or unavailable based on product design or cover artwork.
  • Unbranded Products: allow 3-5 business days for shipping. All Unbranded items receive FREE ground shipping in the US. Inquire for international shipping.
  • RETURNS/CANCELLATIONS: All orders, branded or unbranded, are NON-CANCELLABLE and NON-RETURNABLE once a purchase order has been received.
  • Product Details

    Author:
    John Ansell
    Format:
    Paperback
    Pages:
    282
    Publisher:
    Taylor & Francis (June 24, 2024)
    Language:
    English
    ISBN-13:
    9781032837338
    Dimensions:
    6.875" x 9.6875"
    File:
    TAYLORFRANCIS-TayFran_260122055303581-20260122.xml
    Folder:
    TAYLORFRANCIS
    List Price:
    $55.99
    Country of Origin:
    United States
    As low as:
    $53.19
    Publisher Identifier:
    P-CRC
    Discount Code:
    H
    Pub Discount:
    30
    Weight:
    20.5oz
    Case Pack:
    12
    Imprint:
    Routledge
  • Overview

    Transforming Big Pharma addresses critically how strategy works in the pharmaceutical industry. John Ansell assesses the wide range of alternative strategies big pharma has been attempting in order to make up the shortfall in revenues stemming from the long-standing failure to develop sufficient new products. He shows that there is sound evidence t